Biotech Integrated Solutions – Accelerate Speed to Market
30th September 2021 | | Dave Sokolowski, Global Product Manager, Integrated Solutions, Pall Corporation and Kevin Thompson, Technical Director, Pall Advanced Separation Systems (PASS), Pall Corporation |WATCH FOR FREE
Scaling gene therapy, mAb, or vaccine therapeutic drug products from bench to manufacturing involves a balancing act between project management, risk mitigation, and process parameter selection. A holistically executed development that takes these into consideration can help identify and mitigate risks before they occur and protect the project budget – ultimately accelerating speed to market.
Join Pall’s Technical Director, Kevin Thompson, as he explores the ways Pall Corporation applies best practices through the implementation of the Biotech Integrated Solutions service architecture for large-scale manufacturing projects.